Why Eye Injections Are Used to Treat Diabetic Eye Disease
How Diabetes Damages the Blood Vessels in Your Eye
Diabetes affects far more than blood sugar. Over months and years, it quietly injures the tiny blood vessels throughout the body, and the vessels feeding the retina, the light-sensing tissue at the back of the eye, are among the most vulnerable. Understanding what happens inside the eye makes it easier to understand why the treatments work the way they do.
When blood sugar stays elevated for long periods, it slowly damages the inner lining of very small blood vessels. The retina depends entirely on these tiny vessels for oxygen and nutrients. As they weaken, they begin to leak fluid, close off, or grow in places they should not, setting off a chain of changes that can threaten vision.
The retina works like the film in a camera. It needs a steady supply of oxygen to convert light into the signals your brain reads as vision. When diabetes cuts off that oxygen supply, the retina sends out chemical alarm signals asking for new blood vessels to form. In a healthy body this would be a helpful repair response, but in a diabetic eye it triggers changes that cause further damage.
One of the earliest signs of damage is leakage. Weak spots on the vessel walls, called microaneurysms, drip fluid and fatty deposits into the retina. When fluid collects in the macula, the small central area you use for reading and recognizing faces, it causes swelling called diabetic macular edema. This pushes the retinal layers apart and blurs or distorts vision.
- Fluid builds up in the macula, the part of the retina responsible for sharp central vision
- Fatty deposits can form, appearing as yellow spots during an eye exam
- Vision often changes gradually, which is why regular exams are important even when nothing feels different
In more advanced stages, the eye tries to replace lost vessels by growing new ones. These new vessels are fragile and poorly formed. They can bleed into the gel that fills the eye, pull on the retina, and in serious cases cause the retina to detach. This stage is called proliferative diabetic retinopathy and is one of the main reasons diabetic eye disease can lead to severe vision loss if left untreated.
The main signal behind these changes is a protein called vascular endothelial growth factor, or VEGF. VEGF tells blood vessels to grow and to become more leaky. In a diabetic eye, VEGF levels rise too high, which is what causes swelling and abnormal vessel growth in the first place. Reducing VEGF activity is the central goal of eye injection therapy.
What Anti-VEGF Injections Do Inside Your Eye
Anti-VEGF medicines are specially designed proteins that attach to VEGF molecules and prevent them from acting on blood vessel walls. Once the signal is blocked, leaking slows, abnormal vessels settle down, and the retina has a chance to recover. This is why injections have become the preferred treatment for most forms of diabetic eye disease involving the macula.
When anti-VEGF medicine is injected into the eye, it binds to VEGF molecules floating in the vitreous gel. Once captured, VEGF can no longer attach to the receptors on vessel walls that would normally read its message. With that signal blocked, vessels stop leaking as much and stop growing where they should not.
As VEGF is suppressed, the leaky spots on retinal vessels begin to tighten. Fluid that has pooled in the macula is gradually reabsorbed by the eye. As the swelling goes down, the retinal layers move back toward their normal position, and vision often improves. Some improvement can begin within days to weeks, though the full benefit usually builds over several monthly treatments.
Anti-VEGF medicine also acts on the fragile new vessels that form in advanced diabetic retinopathy. Without a constant VEGF signal to fuel their growth, many of these abnormal vessels shrink back or stop forming new branches. This lowers the risk of bleeding inside the eye and reduces the pulling force on the retina.
- Swelling in the macula decreases, which can sharpen central vision
- Abnormal new vessels become less active and less likely to bleed
- The overall stage of diabetic retinopathy can improve with consistent treatment
The medicine does not change the underlying diabetes, and the body continues to produce VEGF. Over weeks, the injected medicine is gradually cleared from the eye, and VEGF levels begin to rise again. This is why injections are given on a schedule, often every four to eight weeks at first, and then spaced out as the eye stabilizes. Your specialist will adjust the timing based on retinal scans and how your vision holds up between visits.
Because the medicine is placed directly inside the eye, it acts mainly where it is needed. Very little of it travels into the rest of the body. This is a meaningful advantage over a pill or an IV, which would spread throughout the entire body before reaching the retina. Keeping the treatment local reduces the chance of side effects in organs that have nothing to do with the eye problem.
Which Diabetic Eye Conditions Are Treated With Injections
Eye injections are used for several related conditions that develop when diabetes damages the blood vessels in and around the retina. The right treatment depends on which condition is present, how far it has progressed, and how the eye responds over time.
Diabetic macular edema, often called DME, is the most common reason injections are used in diabetic eye care. It occurs when leaking retinal vessels cause fluid to pool in the macula, the area responsible for reading, driving, and recognizing faces. Anti-VEGF injections are the first-choice treatment for center-involving DME because they reduce swelling and often improve vision more reliably than older laser approaches. The diagnosis is confirmed using a scan called optical coherence tomography, which shows a detailed cross-section of the retina.
Proliferative diabetic retinopathy is the advanced stage where abnormal new vessels grow on the surface of the retina or the optic nerve. Injections can cause many of these vessels to shrink, and they are often used either alongside or instead of laser treatment. For some patients, injections offer a way to manage advanced disease without some of the lasting side effects that laser can have on side and night vision.
When fragile new vessels rupture and bleed into the vitreous gel that fills the eye, vision can suddenly become cloudy or filled with dark floating spots. Injections help in these situations by lowering VEGF levels and reducing the drive for more abnormal vessels to grow and bleed. In some cases this allows the eye to clear on its own while avoiding surgery, though your specialist will decide whether additional steps are needed based on how much blood is present.
In severe diabetic eye disease, abnormal vessels can grow on the drainage structures inside the eye, blocking the normal outflow of fluid and raising eye pressure. This condition is called neovascular glaucoma. Anti-VEGF injections are often part of the treatment because they can cause those blocking vessels to regress, and they are usually combined with pressure-lowering drops or other procedures to protect the optic nerve.
Injections are sometimes given in the days before diabetic eye surgery to calm active new vessels and reduce the risk of bleeding during the procedure. They may also be used after surgery to help the retina settle. Your specialist will explain whether this applies to your situation and what the plan involves.
Why Drops, Pills, and IV Treatments Are Not Used Instead
It is a reasonable question to ask why a drop or a pill cannot do the same job. The answer comes down to how the eye is built and how anti-VEGF medicines work. Each alternative falls short for a different reason, and understanding why helps explain why the injection approach makes sense.
The eye has a built-in shield called the blood-retinal barrier that keeps most substances in the bloodstream from entering the delicate retinal tissue. This barrier protects the retina from harmful chemicals and infections in everyday life. The downside is that it also blocks most medicines taken by mouth or given through an IV from reaching the inside of the eye in useful amounts.
Eye drops work well for treating the surface of the eye and the front chamber because those structures sit close to where the drop lands. The retina, however, is at the very back of the eye, separated from the drop by the lens, the iris, and the vitreous gel. Anti-VEGF medicines are also large protein molecules that cannot cross these barriers in meaningful amounts. Almost none of what a drop contains ever reaches the retina.
A pill strong enough to push anti-VEGF medicine through the body and into the eye in useful amounts would expose every organ to the same drug. VEGF plays helpful roles throughout the body, including supporting normal blood vessels and wound healing, so blocking it everywhere at once could interfere with those normal functions. A small dose placed inside the eye avoids that problem by acting mostly where it is needed.
- Drops cannot cross the layers of the eye to reach the retina in useful amounts
- Pills and IV infusions would expose the entire body to a medicine meant for one small area
- Direct injection puts a tiny, concentrated dose right next to the retina where VEGF is being produced
Placing medicine into the vitreous gel puts it right next to the retina, where it spreads out over the retinal surface and stays concentrated where VEGF is being produced. The tiny volume needed is a fraction of what a pill or IV would require, and very little of it escapes back into the rest of the body. This approach, called intravitreal injection, has become the standard for treating diabetic retinopathy and diabetic macular edema because of how reliably it works.
How Injections Compare With Laser and Other Treatments
Eye injections did not replace laser treatment entirely. Laser still plays an important role, especially in advanced disease, but the two approaches work differently and are chosen based on what the retina needs at a given stage. Understanding the comparison helps set realistic expectations.
Before anti-VEGF injections became available, the main treatment for diabetic macular edema was a focal laser that sealed off leaking microaneurysms one by one. This approach could stabilize vision for many people, but it rarely improved vision, and a meaningful number of cases did not respond well. That gap in outcomes is what pushed researchers toward something more effective.
When anti-VEGF medicines were tested in diabetic macular edema, they did something focal laser usually could not: they actually improved reading vision for a large share of patients instead of just keeping it steady. Research comparing the two approaches showed clear benefits with injections, and guidelines changed accordingly. Anti-VEGF became the first-choice treatment for center-involving diabetic macular edema, with laser reserved for specific situations.
For proliferative diabetic retinopathy, a broader type of laser called panretinal photocoagulation remains important. It treats large areas of the outer retina with many small laser spots, lowering the retina's oxygen demand and reducing the drive to grow abnormal vessels. It is reliable and typically completed in one or two sessions, but it can cause some reduction in side vision and night vision. Anti-VEGF injections can be used alone or alongside panretinal laser depending on the situation and the patient's needs.
Steroid medicines can also be injected into the eye to reduce swelling in diabetic macular edema. They are usually considered when anti-VEGF injections are not the right fit or when the response to anti-VEGF has been limited. Steroid injections last longer between doses but can raise eye pressure and accelerate cataract formation. Your specialist will weigh these factors carefully before choosing a plan.
In real-world diabetic eye care, treatment is rarely one approach for life. Many patients receive a combination at different points: injections to quiet swelling, laser for specific areas, and sometimes surgery for bleeding or scar tissue. Your specialist selects the mix based on which part of the eye is affected, how much vision is at risk, and how well you respond over time. The goal throughout is to preserve as much useful vision as possible.
What to Expect at an Injection Visit
Knowing what happens during an injection visit helps reduce anxiety and makes it easier to plan your day. The procedure itself is brief, and most patients are surprised by how manageable it feels once they have been through it a few times.
On the day of the injection, your specialist will typically check your vision, examine the retina, and often take a scan of the macula to compare with previous visits. The eye is then numbed with drops, and sometimes a small amount of numbing gel or a cotton swab soaked in numbing medicine is placed near the eyelid. A sterile cleaning solution is applied around the eye to reduce the risk of infection, and a small device gently holds the eyelids open so blinking is not a concern.
The injection is given through the white part of the eye, called the sclera, a few millimeters behind the colored iris. Most people feel only a brief pressure or a mild pinch. The needle is very thin and the volume of medicine is tiny, so the process takes only a few seconds. Your specialist may ask you to look in a specific direction so the needle enters a safe area away from the lens and the central retina.
After the injection, the eye is rinsed and checked. It is common to see floaters or a small air bubble moving around in your vision for a day or so, and the eye may feel scratchy because of the cleaning solution. Artificial tears usually help with the scratchiness, and vision may be slightly blurry for a few hours. Driving yourself home is generally not recommended on your first visit until you know how you react.
- Mild redness where the needle entered is common and typically fades within a few days
- Floaters or a small bubble in your view usually clear on their own
- Sharp pain, sudden vision loss, or increasing redness should prompt immediate contact with your eye care team
Anti-VEGF injections usually begin with a loading period, often one injection per month for several months, to bring the retina under control. After that, the spacing is adjusted based on how the eye responds. Some patients stay on monthly treatment, others stretch to every two or three months, and some can take longer breaks between shots. Your specialist uses scans and vision tests at each visit to guide these decisions.
Keeping blood sugar, blood pressure, and cholesterol well managed makes injections work more effectively and last longer. It is common for patients to get more out of their treatment once overall diabetes control improves. Regular appointments also matter because changes in the retina can develop without any noticeable symptoms. Showing up for each scheduled visit is one of the most important things you can do for your vision.
Frequently Asked Questions
The questions below address specific points that often come up when patients are deciding how to approach injection treatment for diabetic eye disease.
Some patients notice a small improvement within days as swelling begins to drop, while others need several weeks to feel a change. Scans of the retina often show measurable improvement before you can detect it yourself. Larger gains in vision typically build after the first three to six monthly injections, which is why the early loading phase is given consistently without gaps. Your specialist will track your progress at every visit using both vision testing and retinal imaging.
Not necessarily, though many patients do continue treatment for a long time. Some people are able to extend the time between injections significantly as their retina stabilizes, and a smaller number can eventually pause treatment under close monitoring. The answer depends on how your retina responds, how well your diabetes is managed overall, and whether VEGF levels remain suppressed between doses. Your specialist will reassess the plan regularly rather than assuming any fixed schedule is permanent.
Serious complications from intravitreal injections are uncommon but not impossible. The most significant risk is a rare infection inside the eye called endophthalmitis, which is why thorough sterile preparation before each injection is so important. Other risks include temporary elevated eye pressure, small subconjunctival hemorrhages (red spots on the white of the eye), and in rare cases retinal detachment. Your specialist follows strict safety protocols at every visit to minimize these risks, and knowing the warning signs, such as sharp pain or sudden vision loss, allows for prompt treatment if a problem does arise.
Skipping injections because vision feels normal is one of the most common reasons treatment loses ground. The medicine works partly by staying ahead of VEGF activity, and gaps in treatment can allow swelling or abnormal vessel growth to return before you notice any change. Retinal scans often detect worsening before symptoms appear. Sticking to your scheduled appointments, even when things seem stable, gives your specialist the information needed to safely extend or adjust the interval rather than having to restart from the beginning.
Laser and injections are not competing treatments so much as tools used at different stages and for different purposes. Panretinal photocoagulation laser remains important for advanced proliferative disease and is particularly valuable when patients cannot reliably return for frequent injection visits. Focal laser may still be used for specific leaking areas outside the central macula. Your specialist evaluates which approach, or combination of approaches, gives your eye the best chance of long-term stability based on your exact diagnosis and lifestyle.
Yes, and the connection is well established. Better blood sugar control reduces the ongoing stimulus that causes VEGF to rise in the first place, which means each injection can do more with less opposition. Patients who improve their systemic diabetes management during treatment often find that their retina responds more robustly and that intervals between injections can be extended sooner. Coordinating with your primary care provider or endocrinologist alongside your eye care is one of the most practical steps you can take to support your vision outcomes.
Visit Us to Protect Your Vision
At Retina Associates of Greater Philadelphia, our specialists are dedicated to providing expert, personalized care for patients facing diabetic eye disease across the greater Philadelphia region and Southern New Jersey. We combine advanced diagnostic imaging with proven treatment strategies to give every patient the best possible chance of preserving their vision. If you have been referred for injection therapy or have questions about your diabetic eye health, we welcome the opportunity to guide you through every step of your care.
Staff very efficient and polite. Dr Linares very nice, knowledgeable and explains things in layman terms.
Theresa Interlante
Always a pleasure to visit Dr. Linares’ Sewell office. Everyone is professional and welcoming. Very short wait-time if at all.
Honora Lopez
Dr Kleiner is super nice, very thorough and knowledgeable. She listens to you!
Anthony Bonagura
Staff was very friendly and efficient. I was a new patient add on and it didn’t feel that way.
F.T
i love the staff, very friendly and doctor is very helpful and very friendly, it’s very clean. it’s a awesome place to visit for your eyes care
Melody Sanders